EcoR1 leads Jun 26 whale moves

The freshest ownership tape is more useful than the M&A headlines this morning. In the filing window from June 25, 8:27 a.m. ET to June 26, 8:00 a.m. ET, the clearest followable signals came from three buckets: biotech specialists crossing 5% thresholds, activists resetting positions, and a few stress exits where the filing itself says more than the headline.

The highest-signal read: EcoR1 Capital opened a 9.0% passive stake in Fulcrum Therapeutics, while Steel Partners paired an 18.7% Spruce Power stake with a board nomination. 1 2 Those are different kinds of whale moves. EcoR1 crossed a passive disclosure line; Steel Partners is already in engagement mode.

The cleanest buying signal is not always the largest percentage. A 13D with governance action usually outranks a passive 13G, because the filer is telling the market it may influence the issuer rather than merely hold shares. Steel Partners' Spruce filing therefore sits above several larger-looking passive disclosures, even though EcoR1's Fulcrum filing is the healthcare name most likely to attract biotech screens.

The healthcare cluster is real but mixed. EcoR1 disclosed Fulcrum, Baselake disclosed Passage Bio, and Avenue Venture Opportunities Fund II amended its CalciMedica position with a 4.99% blocker tied to a loan amendment and conversion rights. Avenue reports 4,641,163 shares on a fully diluted basis, with $10 million principal outstanding and up to $3 million convertible at $1.00 per share. 10 That is healthcare exposure, but it is a financing-structure signal more than a clean open-market accumulation signal.

The exit side is more direct. Takeover Time's Aditxt filing reports a full sale to zero, and Helena Global's DevvStream filing reports a full exit days after a prior 9.82% disclosure. 6 7 For readers looking for copyable moves, those filings are better treated as risk flags than as long ideas.

The M&A tape stayed busy. onsemi agreed to acquire Synaptics in an all-stock transaction valued at about $7 billion, with Synaptics holders receiving 1.350 onsemi shares per Synaptics share and an implied 19% premium to the 10-day volume-weighted average price. 11 The deal targets mid-2027 closing, and the agreement includes a $235 million Synaptics termination fee plus a $320 million onsemi regulatory termination fee. 11

Bio-Techne also remains on the board after Merck KGaA filed definitive merger materials for an $11.3 billion all-cash acquisition at $73.00 per share, a 36% premium to Bio-Techne's one-month volume-weighted average price. 12 The fresh read today is narrower: watch whether arbitrage funds and event-driven holders begin crossing reporting thresholds as the deal moves toward a late-2026 or early-2027 close. 12

For the next daily read, the main filter is simple: give more weight to filings that combine a holder above 5%, an active Schedule 13D, and a near-term corporate catalyst. Passive 13Gs are useful alerts, but the follow trade usually needs a second signal: a specialist holder, a board seat, a financing trigger, or a deal deadline.